View Filing Data

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2014	Oct. 31, 2014
Document and Entity Information
Entity Registrant Name	AMICUS THERAPEUTICS INC
Entity Central Index Key	0001178879
Document Type	10-Q
Document Period End Date	Sep. 30, 2014
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		79,321,630
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q3

Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$ 19,671	$ 43,640
Investments in marketable securities	65,511	38,360
Receivable due from collaboration agreements	293	1,083
Prepaid expenses and other current assets	1,762	5,195
Total current assets	87,237	88,278
Property and equipment, less accumulated depreciation and amortization of $9,973 and $11,157 at December 31, 2013 and September 30, 2014, respectively	3,129	4,120
In-process research & development	23,000	23,000
Goodwill	11,613	11,613
Other non-current assets	508	552
Total Assets	125,487	127,563
Current liabilities:
Accounts payable and accrued expenses	11,331	10,162
Current portion of secured loan	2,493	299
Total current liabilities	13,824	10,461
Deferred reimbursements	36,677	36,677
Secured loan, less current portion	11,809	14,174
Contingent consideration payable	10,200	10,600
Deferred tax liability	9,186	9,186
Other non-current liability	514	714
Commitments and contingencies
Stockholders' equity:
Common stock, $.01 par value, 125,000,000 shares authorized, 61,975,416 shares issued and outstanding at December 31, 2013, 125,000,000 shares authorized, 79,257,588 shares issued and outstanding at September 30, 2014	853	679
Additional paid-in capital	468,650	423,593
Accumulated other comprehensive income	2	1
Accumulated deficit	(426,228)	(378,522)
Total stockholders' equity	43,277	45,751
Total Liabilities and Stockholders' Equity	$ 125,487	$ 127,563

Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenue:
Research revenue	$ 293	$ 39	$ 1,224	$ 39
Total revenue	293	39	1,224	39
Operating Expenses:
Research and development	12,049	10,110	32,019	32,824
General and administrative	5,270	4,635	15,199	14,288
Changes in fair value of contingent consideration payable	(600)		(400)
Restructuring charges	15		(74)
Depreciation and amortization	375	429	1,183	1,318
Total operating expenses	17,109	15,174	47,927	48,430
Loss from operations	(16,816)	(15,135)	(46,703)	(48,391)
Other income (expenses):
Interest income	55	36	133	147
Interest expense	(377)	(7)	(1,106)	(26)
Change in fair value of warrant liability		517		874
Other expense	(11)		(30)
Net loss	$ (17,149)	$ (14,589)	$ (47,706)	$ (47,396)
Net loss per common shares - basic and diluted (in dollars per share)	$ (0.22)	$ (0.29)	$ (0.68)	$ (0.96)
Weighted-average common shares outstanding - basic and diluted (in shares)	78,889,346	49,621,188	70,216,251	49,621,188

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Consolidated Statements of Comprehensive Loss
Net loss	$ (17,149)	$ (14,589)	$ (47,706)	$ (47,396)
Other comprehensive (loss)/income:
Unrealized gain/ (loss) on available-for-sale securities	4	2	1	(9)
Other comprehensive gain/ (loss) before income taxes	4	2	1	(9)
Other comprehensive gain/ (loss)	4	2	1	(9)
Comprehensive loss	$ (17,145)	$ (14,587)	$ (47,705)	$ (47,405)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9

+ Details

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Operating activities
Net loss	$ (47,706)	$ (47,396)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash interest expense	176
Depreciation and amortization	1,183	1,318
Stock-based compensation	4,398	4,674
Restructuring charges	(74)
Change in fair value of warrant liability		(874)
Non-cash changes in the fair value of contingent consideration payable	(400)
Changes in operating assets and liabilities:
Receivable due from collaboration agreements	790	1,064
Prepaid expenses and other current assets	3,433	618
Other non-current assets	26
Accounts payable and accrued expenses	1,213	(679)
Non-current liabilities	(200)
Deferred reimbursements		3,601
Net cash used in operating activities	(37,161)	(37,674)
Investing activities
Sale and redemption of marketable securities	47,959	68,348
Purchases of marketable securities	(75,109)	(33,654)
Purchases of property and equipment	(192)	(645)
Net cash provided by/(used in) investing activities	(27,342)	34,049
Financing activities
Proceeds from issuance of common stock, net of issuance costs	38,736
Payments of secured loan agreement	(299)	(299)
Proceeds from exercise of stock options	2,097
Net cash (used in)/provided by financing activities	40,534	(299)
Net decrease in cash and cash equivalents	(23,969)	(3,924)
Cash and cash equivalents at beginning of period	43,640	33,971
Cash and cash equivalents at end of period	19,671	30,047
Supplemental disclosures of cash flow information
Cash paid during the period for interest	$ 864	$ 24

Description of Business and Significant Accounting Policies	9 Months Ended
	Sep. 30, 2014
Description of Business and Significant Accounting Policies
Description of Business and Significant Accounting Policies	Note 1. Description of Business and Significant Accounting Policies *Corporate Information, Status of Operations and Management Plans* Amicus Therapeutics, Inc. (the Company) was incorporated on February 4, 2002 in Delaware and is a biopharmaceutical company focused on the discovery, development and commercialization of next-generation medicines for a range of rare and orphan diseases, with a focus on improved therapies for lysosomal storage diseases (LSDs). The Company’s lead program is migalastat HCl (migalastat) for Fabry disease. Migalastat is a novel, small molecule pharmacological chaperone in development as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The Company is leveraging its Chaperone-Advanced Replacement Therapy, or CHART™ platform along with other proprietary technologies to develop next-generation ERTs for Fabry, Pompe, Mucopolysaccharidosis Type I (MPS I) and Gaucher diseases. The Company’s activities since inception have consisted principally of raising capital, establishing facilities, and performing research and development. In August 2014, the Company announced positive 18 month data from the Study 012. A summary of the 18-month results are as follows: · Migalastat had a comparable effect to ERT on patients’ kidney function as measured by the change in eGFR and mGFR. · Levels of plasma lyso-Gb3, an important biomarker of disease, remained low and stable in patients with amenable mutations who switched from ERT to migalastat. · Migalastat was generally safe and well-tolerated. · Of 48 patients with GLP HEK-amenable mutations who completed Study 012, 46 (96%) elected to continue with the 12-month treatment extension and 45 remain on migalastat today as their only treatment for Fabry disease. The Company looks forward to meeting with the EMEA in the fourth quarter of 2014 and the US FDA early in 2015 to make migalastat available for all amenable Fabry patients as quickly as possible. In July 2014, the Company completed a $40 million at the market (ATM) equity offering under which the Company sold shares of its common stock, par value $0.01 per share, with Cowen and Company LLC as sales agent. Under the ATM equity program, the Company sold 14.3 million shares of common stock raising approximately $38.7 million in net proceeds. For further information on the ATM Agreement, see — Note 7. Stockholder’s Equity. In November 2013, the Company completed the acquisition of Callidus Biopharma, Inc. (Callidus). Callidus was a privately-held biologics company focused on developing best-in-class enzyme replacement therapies (ERTs) for lysosomal storage diseases (LSDs). Callidus lead ERT is a recombinant human acid-alpha glucosidase (rhGAA, called ATB200) for Pompe disease in late preclinical development. For further information, see — Note 4. Acquisition of Callidus Biopharma, Inc. In November 2013, Amicus entered into the Revised Agreement (the Revised Agreement) with GlaxoSmithKline plc (GSK), pursuant to which Amicus has obtained global rights to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease. The Revised Agreement amends and replaces in its entirety the Expanded Agreement entered into between Amicus and GSK in July 2012 (the Expanded Collaboration Agreement). Under the terms of the Revised Agreement, Amicus obtained global commercial rights to migalastat, both as a monotherapy and co-formulated with ERT. For the next-generation Fabry ERT (migalastat co-formulated with ERT), GSK is eligible to receive single-digit royalties on net sales in eight major markets outside the U.S. For migalastat monotherapy, GSK is eligible to receive post-approval and sales-based milestones, as well as tiered royalties in the mid-teens in eight major markets outside the U.S. There was no other consideration paid to GSK as part of the Revised Agreement. In November 2013, the Company entered into a securities purchase agreement (the 2013 SPA) with certain entities controlled by Redmile Group, LLC and GSK for the private placement of a combination of shares of the Company’s common stock and warrants to purchase shares of the Company’s common stock. The warrants have a term of one year and are exercisable between July 1, 2014 and June 30, 2015 at an exercise price of $2.50 per share. The aggregate offer proceeds were $15 million. In September 2013, the Company entered into a collaboration agreement with Biogen Idec (Biogen) to discover, develop and commercialize novel small molecules that target the glucocerobrosidase (GCase) enzyme for the treatment of Parkinson’s disease. In September 2014, the Company and Biogen concluded their research collaboration. Amicus’ most advanced Parkinson’s candidate is AT3375, which was developed outside the collaboration and is wholly-owned by Amicus. For further information, see — Note 10. Collaborative Agreements. The Company had an accumulated deficit of approximately $426.2 million at September 30, 2014 and anticipates incurring losses through the fiscal year ending December 31, 2014 and beyond. The Company has not yet generated commercial sales revenue and has been able to fund its operating losses to date through the sale of its redeemable convertible preferred stock, issuance of convertible notes, net proceeds from its initial public offering (IPO) and subsequent stock offerings, payments from partners during the terms of the collaboration agreements and other financing arrangements. Including the net proceeds from the completed ATM equity program, the Company believes that its existing cash and cash equivalents and short-term investments will be sufficient to fund the current operating plan into 2016. *Basis of Presentation* The Company has prepared the accompanying unaudited consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10-01 of Regulations S-X. Accordingly, they do not include all of the information and disclosures required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying unaudited financial statements reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s interim financial information. The accompanying unaudited consolidated financial statements and related notes should be read in conjunction with the Company’s financial statements and related notes as contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013. For a complete description of the Company’s accounting policies, please refer to the Annual Report on Form 10-K for the fiscal year ended December 31, 2013. *Significant Accounting Policies* There have been no material changes to the Company’s significant accounting policies during the three months ended September 30, 2014, as compared to the significant accounting policies disclosed in Note 2 of the Consolidated Financial Statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013, except for the adoption of Accounting Standards Update (ASU) 2014-10, as described below. However, the following accounting policies are the most critical in fully understanding and evaluating the Company’s financial condition and results of operations. Revenue Recognition The Company recognizes revenue when amounts are realized or realizable and earned. Revenue is considered realizable and earned when the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the price is fixed or determinable; and (4) collection of the amounts due are reasonably assured. In multiple element arrangements, revenue is allocated to each separate unit of accounting and each deliverable in an arrangement is evaluated to determine whether it represents separate units of accounting. A deliverable constitutes a separate unit of accounting when it has standalone value and there is no general right of return for the delivered elements. In instances when the aforementioned criteria are not met, the deliverable is combined with the undelivered elements and the allocation of the arrangement consideration and revenue recognition is determined for the combined unit as a single unit of accounting. Allocation of the consideration is determined at arrangement inception on the basis of each unit’s relative selling price. In instances where there is determined to be a single unit of accounting, the total consideration is applied as revenue for the single unit of accounting and is recognized over the period of inception through the date where the last deliverable within the single unit of accounting is expected to be delivered. The Company’s current revenue recognition policies, which were applied in fiscal 2010, provide that, when a collaboration arrangement contains multiple deliverables, such as license and research and development services, the Company allocates revenue to each separate unit of accounting based on a selling price hierarchy. The selling price hierarchy for a deliverable is based on (i) its vendor specific objective evidence (VSOE) if available, (ii) third party evidence (TPE) if VSOE is not available, or (iii) best estimated selling price (BESP) if neither VSOE nor TPE is available. The Company would establish the VSOE of selling price using the price charged for a deliverable when sold separately. The TPE of selling price would be established by evaluating largely similar and interchangeable competitor products or services in standalone sales to similarly situated customers. The BESP would be established considering internal factors such as an internal pricing analysis or an income approach using a discounted cash flow model. The Company also considers the impact of potential future payments it makes in its role as a vendor to its customers and evaluates if these potential future payments could be a reduction of revenue from that customer. If the potential future payments to the customer are: · a payment for an identifiable benefit; and · the identifiable benefit is separable from the existing relationship between the Company and its customer; and · the identifiable benefit can be obtained from a party other than the customer; and · the Company can reasonably estimate the fair value of the identifiable benefit, then the payments are accounted for separate from the revenue received from that customer. If, however, all these criteria are not satisfied, then the payments are treated as a reduction of revenue from that customer. If the Company determines that any potential future payments to its customers are to be considered as a reduction of revenue, it must evaluate if the total amount of revenue to be received under the arrangement is fixed and determinable. If the total amount of revenue is not fixed and determinable due to the uncertain nature of the potential future payments to the customer, then any customer payments cannot be recognized as revenue until the total arrangement consideration becomes fixed and determinable. The reimbursements for research and development costs under collaboration agreements that meet the criteria for revenue recognition are included in Research Revenue and the costs associated with these reimbursable amounts are included in research and development expenses. In order to determine the revenue recognition for contingent milestones, the Company evaluates the contingent milestones using the criteria as provided by the Financial Accounting Standards Boards (FASB) guidance on the milestone method of revenue recognition at the inception of a collaboration agreement. The criteria requires that (i) the Company determines if the milestone is commensurate with either its performance to achieve the milestone or the enhancement of value resulting from the Company’s activities to achieve the milestone, (ii) the milestone be related to past performance, and (iii) the milestone be reasonable relative to all deliverable and payment terms of the collaboration arrangement. If these criteria are met then the contingent milestones can be considered as substantive milestones and will be recognized as revenue in the period that the milestone is achieved. Although the Company believes the assumptions and estimates made are reasonable, they are based in part on historical experience and information obtained from the management of the acquired businesses and are inherently uncertain. Examples of critical estimates in valuing any contingent acquisition consideration issued or which may be issued and the intangible assets we have acquired or may acquire in the future include but are not limited to: · the feasibility and timing of achievement of development, regulatory and commercial milestones; · expected costs to develop the in-process research and development into commercially viable products; and · future expected cash flows from product sales. Unanticipated events and circumstances may occur which may affect the accuracy or validity of such assumptions, estimates or actual results. Fair Value Measurements The Company records certain asset and liability balances under the fair value measurements as defined by the FASB guidance. Current FASB fair value guidance emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, current FASB guidance establishes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity’s own assumptions that market participants assumptions would use in pricing assets or liabilities (unobservable inputs classified within Level 3 of the hierarchy). Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at measurement date. Level 2 inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals. Level 3 inputs are unobservable inputs for the asset or liability, which is typically based on an entity’s own assumptions, as there is little, if any, related market activity. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability. *New Accounting Standards* In August 2014, the FASB issued ASU 2014-15, “Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (ASU 2014-15), which defines management’s responsibility to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosures if there is substantial doubt about its ability to continue as a going concern. The pronouncement is effective for annual reporting periods ending after December 15, 2016 with early adoption permitted. The adoption of this guidance is not expected to have a significant impact on the Company’s consolidated financial statements. In June 2014, the FASB issued ASU 2014-10 that removes the definition of development stage entity from the accounting standards codification, thereby removing the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the ASU eliminates the requirements for development stage entities to (i) present inception-to-date information in the statement of income, cash flow and stockholders’ equity, (ii) label the financial statements as those of a development stage entity, (iii) disclose a description of the development stage activities in which the entity is engaged, and (iv) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. The Company has applied the ASU effective from the financial statements as of June 30, 2014. In May 2014, FASB issued ASU 2014-09, Revenue From Contracts With Customers, that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The ASU is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract. Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard. The ASU becomes effective for the Company at the beginning of its 2017 fiscal year; early adoption is not permitted. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.

Cash, Money Market Funds and Marketable Securities

9 Months Ended

Sep. 30, 2014

Cash, Money Market Funds and Marketable Securities

Cash, Money Market Funds and Marketable Securities

Note 2. Cash, Money Market Funds and Marketable Securities

As of September 30, 2014, the Company held $19.7 million in cash and cash equivalents and $65.5 million of available-for-sale investment securities which are reported at fair value on the Company’s balance sheet. Unrealized holding gains and losses are reported within accumulated comprehensive income/ (loss) in the statement of comprehensive loss. If a decline in the fair value of a marketable security below the Company’s cost basis is determined to be other than temporary, such marketable security is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge. To date, only temporary impairment adjustments have been recorded.

Consistent with the Company’s investment policy, the Company does not use derivative financial instruments in its investment portfolio. The Company regularly invests excess operating cash in deposits with major financial institutions, money market funds, notes issued by the U.S. government, as well as fixed income investments and U.S. bond funds both of which can be readily purchased and sold using established markets. The Company believes that the market risk arising from its holdings of these financial instruments is mitigated as many of these securities are either government backed or of the highest credit rating.

Cash and available-for-sale securities consisted of the following as of December 31, 2013 and September 30, 2014 (in thousands):

	As of December 31, 2013
	Cost		Unrealized Gain		Unrealized Loss			Fair Value
Cash balances	$	43,640	$	—	$	—		$	43,640
Corporate debt securities	30,817		1		(6		)	30,812
Commercial paper	7,192		6		—			7,198
Certificate of deposit	350		—		—			350
	$	81,999	$	7	$	(6	)	$	82,000

Included in cash and cash equivalents	$	43,640	$	—	$	—		$	43,640
Included in marketable securities	38,359		7		(6		)	38,360
Total cash and available for sale securities	$	81,999	$	7	$	(6	)	$	82,000

	As of September 30, 2014
	Cost		Unrealized Gain		Unrealized Loss			Fair Value
Cash balances	$	19,671	$	—	$	—		$	19,671
Corporate debt securities	53,674		1		(13		)	53,662
Commercial paper	11,486		13		—			11,499
Certificate of deposit	350		—		—			350
	$	85,181	$	14	$	(13	)	$	85,182

Included in cash and cash equivalents	$	19,671	$	—	$	—		$	19,671
Included in marketable securities	65,510		14		(13		)	65,511
Total cash and available for sale securities	$	85,181	$	14	$	(13	)	$	85,182

Unrealized gains and losses are reported as a component of other comprehensive income/(loss) in the statements of comprehensive loss. For the year ended December 31, 2013, unrealized holding loss of $13 thousand and for the nine months ended September 30, 2014, unrealized holding gain of $1 thousand, were recognized.

For the year ended December 31, 2013 and the nine months ended September 30, 2014, there were no realized gains or losses. The cost of securities sold is based on the specific identification method.

Unrealized loss positions in the available for sale securities as of December 31, 2013 and September 30, 2014 reflect temporary impairments that have not been recognized and have been in a loss position for less than twelve months. The fair value of these available for sale securities in unrealized loss positions was $23.6 million and $42.6 million as of December 31, 2013 and September 30, 2014, respectively.

The Company holds available-for-sale investment securities which are reported at fair value on the Company’s balance sheet. Unrealized holding gains and losses are reported within accumulated other comprehensive income (AOCI) in the statements of comprehensive loss. The changes in AOCI associated with the unrealized holding gain on available-for-sale investments during the three and nine months ended September 30, 2013 and 2014, were as follows (in thousands):

	Three Months Ended September 30,					Nine Months Ended September 30,
	2013		2014			2013			2014

Balance, beginning	$	3	(2		)	$	14		$	1
Current period changes in fair value, (a)	2		4			(9		)	1
Reclassification of earnings, (a)	—		—			—			—
Balance, ending	$	5	$	2		$	5		$	2

(a) — Taxes have not been accrued on the unrealized gain on securities as the Company is in a loss position for all periods presented.

Basic and Diluted Net Loss Attributable to Common Stockholders per Common Share

9 Months Ended

Sep. 30, 2014

Basic and Diluted Net Loss Attributable to Common Stockholders per Common Share

Basic and Diluted Net Loss Attributable to Common Stockholders per Common Share

Note 3. Basic and Diluted Net Loss Attributable to Common Stockholders per Common Share

The Company calculates net loss per share as a measurement of the Company’s performance while giving effect to all dilutive potential common shares that were outstanding during the reporting period. The Company has a net loss for all periods presented; accordingly, the inclusion of common stock options and warrants would be anti-dilutive. Therefore, the weighted average shares used to calculate both basic and diluted earnings per share are the same.

The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss attributable to common stockholders per common share:

	Three Months Ended September 30,						Nine Months Ended September 30,
(In thousands, except per share amounts)	2013			2014			2013			2014
Historical
Numerator:
Net loss attributable to common stockholders per common	$	(14,589	)	$	(17,149	)	$	(47,396	)	$	(47,706	)

Denominator
Weighted average common shares outstanding — basic and diluted	49,621,188			78,889,346			49,621,188			70,216,251

Dilutive common stock equivalents would include the dilutive effect of common stock options, restricted stock units and warrants for common stock equivalents. Potentially dilutive common stock equivalents were excluded from the diluted earnings per share denominator for all periods because of their anti-dilutive effect. The table below presents potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method (in thousands):

	As of September 30,
	2013	2014
Options to purchase common stock	10,112	10,329
Outstanding warrants, convertible to common stock	1,404	1,600
Unvested restricted stock units	—	955
Total number of potentially issuable shares	11,516	12,884

Acquisition of Callidus Biopharma, Inc.

9 Months Ended

Sep. 30, 2014

Acquisition of Callidus Biopharma, Inc.

Acquisition of Callidus Biopharma, Inc.

Note 4. Acquisition of Callidus Biopharma, Inc.

In November 2013, the Company acquired Callidus, through the merger of the Company’s subsidiary, CB Acquisition Corp. with and into Callidus (see — Note 1. Description of Business). Callidus was a privately-held biologics company focused on developing best-in-class ERTs for LSDs and its lead ERT is ATB200 for Pompe disease in late preclinical development. The acquisition of the Callidus assets and technology complements Amicus’ CHART™ platform for the development of next generation ERTs.

In consideration for the merger, the Company agreed to issue an aggregate of 7.2 million shares of its common stock, par value $0.01 per share, to the former stockholders of Callidus. As of September 30, 2014, approximately 25 thousand shares remain issuable to former Callidus shareholders. In addition, the Company will be obligated to make additional payments to the former stockholders of Callidus upon the achievement by the Company of certain clinical milestones of up to $35 million and regulatory approval milestones of up to $105 million as set forth in the Merger Agreement, provided that the aggregate consideration shall not exceed $130 million. The Company may, at its election, satisfy certain milestone payments identified in the Merger Agreement aggregating $40 million in shares of its Common Stock (calculated based on a price per share equal to the average of the last closing bid price per share for the Common Stock on The NASDAQ Global Market for the ten (10) trading days immediately preceding the date of payment). The milestone payments not permitted to be satisfied in Common Stock (as well as any payments that the Company is permitted to, but chooses not to, satisfy in Common Stock), as a result of the terms of the Merger Agreement, the rules of The NASDAQ Global Market, or otherwise, will be paid in cash.

The fair value of the contingent acquisition consideration payments on the acquisition date was $10.6 million and was estimated by applying a probability-based income approach utilizing an appropriate discount rate. This estimation was based on significant inputs that are not observable in the market, referred to as Level 3 inputs. Key assumptions included a discount rate of 13.0% and various probability factors. As of September 30, 2014, the range of outcomes and assumptions used to develop these estimates has changed to better reflect the probability of certain milestone outcomes. (see — Note 8. Assets and Liabilities Measured at Fair Value for additional discussion regarding fair value measurements of the contingent acquisition consideration payable). The Company determined the fair value of the contingent consideration to be $10.2 million at September 30, 2014, resulting in a decrease in the contingent consideration payable and related income of $0.4 million for the nine months ended September 30, 2014.

A substantial portion of the assets acquired consisted of intangible assets related to Callidus lead ERT. The Company determined that the estimated acquisition-date fair values of the IPR&D related to the lead ERT was $23.0 million.

As part of the Callidus acquisition, the Company recognized $9.2 million of deferred tax liabilities, which relates to the tax impact of future amortization or possible impairments associated with the identified intangible assets acquired, and are not deductible for tax purposes. The Company also recorded goodwill in the Company’s consolidated balance sheet as of the acquisition date. The goodwill results from the recognition of the deferred tax liability on the intangible assets as well as synergies expected from the acquisition and other benefits that do not qualify for separate recognition as acquired intangible assets. None of the goodwill is expected to be deductible for income tax purposes. The final valuation of this acquisition was completed on March 31, 2014.

For further information, see — Note 5 Goodwill & — Note 6 Intangible Assets.

Supplemental Pro Forma Information

The following pro forma information for the three and nine months ending September 30, 2013 assumes the Merger Agreement occurred as of January 1, 2013. The pro forma information is not necessarily indicative either of the combined results of operations that actually would have been realized had the Merger Agreement been consummated during the period for which pro forma information is presented, or is it intended to be a projection of future results or trends.

(in thousands)	Three Months ended September 30, 2013			Nine Months ended September 30, 2013
Revenue	$	—		$	—
Net loss	$	(15,838	)	$	(49,569	)

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6996-128479

+ Details

Stockholders' Equity

9 Months Ended

Sep. 30, 2014

Stockholders' Equity

Stockholders' Equity

Note 7. Stockholders’ Equity

Common Stock and Warrants

As of September 30, 2014, the Company was authorized to issue 125 million shares of common stock. Dividends on common stock will be paid when, and if declared by the board of directors. Each holder of common stock is entitled to vote on all matters and is entitled to one vote for each share held.

In March 2014, the Company entered into the Sales Agreement with Cowen to create an ATM equity program under which the Company sold shares of its common stock, par value $0.01 per share, with an aggregate offering price of up to $40 million (ATM Shares) through Cowen. Upon delivery of a placement notice and subject to the terms and conditions of the ATM agreement, Cowen used its commercially reasonable efforts to sell the ATM Shares, based upon the Company’s instructions. The Company had provided Cowen with customary indemnification rights, and Cowen was entitled to a commission at a fixed commission rate of up to 3.0% of the gross proceeds per Share sold. Sales of the ATM Shares under the Sales Agreement were to be made in transactions that were deemed to be “at the market offerings” as defined in Rule 415 under the Securities Act of 1933, as amended, including sales made by means of ordinary brokers’ transactions, including on The NASDAQ Global Market, at market prices or as otherwise agreed with Cowen. The Company began the sale of ATM Shares in May 2014. The Company sold 14.3 million shares of common stock resulting in net proceeds of $38.7 million, which included Cowen’s commission of $1.1 million and legal fees of $0.1 million. The Company completed all sales under the ATM equity program in July 2014.

In November 2013, the Company entered into the 2013 SPA with certain entities controlled by Redmile Group, LLC and GSK and for the private placement of shares of the Company’s common stock, par value $0.01 and a combination of shares of common stock (the Shares) and warrants (the Warrants) to purchase shares of the Common Stock (collectively, the Units). Each of the investors was one of the Company’s shareholders prior to consummation of these transactions. The Shares and the Units sold to the investors were offered and sold in reliance on exemptions from registration pursuant to Rule 506 of Regulation D promulgated under the Securities Act based on the nature of such investors and certain representations made to the Company. Pursuant to the 2013 SPA, Amicus agreed to issue 1.5 million Shares at $2.00 per Share to GSK and (b) 6 million Units at $2.00 per Unit to Redmile Group, with each Unit consisting of one Share and .267 Warrants resulting in an aggregate of 6 million Shares and 1.6 million Warrants underlying the Units to be issued. Each Warrant is exercisable between July 1, 2014 and June 30, 2015 with an exercise price of $2.50, subject to certain adjustments. The Company received total proceeds of $15 million for general corporate and working capital purposes as a result of the private placement and the transaction closed in November 2013.

At the time of issuance the Company evaluated the warrants against current accounting guidance and determined that these warrants should be accounted as a component of equity. As such, these warrants were valued at issuance date using the Black Scholes valuation model using inputs such as the underlying price of the shares issued when the warrant is exercised, volatility, risk free interest rate and expected life of the instrument. The six inputs used to determine the value of the warrants were: (1) the closing price of Amicus stock on the day of evaluation of $2.12; (2) the exercise price of the warrants of $2.50; (3) the remaining term of the warrants of 1 year; (4) the volatility of Amicus’ stock for the one year term of 93.5%; (5) the annual rate of dividends of 0%; and (6) the riskless rate of return of 0.12%. The annual rate of dividends is based on the Company’s historical practice of not granting dividends. The resulting Black Scholes value of the warrants was $1.0 million.

In November 2013, in connection with its acquisition of Callidus, the Company agreed to issue an aggregate of 7.2 million shares of its common stock, par value $0.01 per share, to the former stockholders of Callidus. As of September 30, 2014, approximately 25 thousand shares remain issuable to former Callidus shareholders.

Nonqualified Cash Deferral Plan

In July 2014, the Board of Directors approved the Company’s Cash Deferral Plan (the Deferral Plan), which provides certain key employees and other service providers as selected by the Compensation Committee of the Board of Directors of the Company (the Compensation Committee), with an opportunity to defer the receipt of such Participant’s base salary, bonus and director’s fees, as applicable. The Deferral Plan is intended to be a nonqualified deferred compensation plan that complies with the provisions of Section 409A of the Internal Revenue Code (the Code).

As of September 30, 2014, the amounts deferred under the Deferral Plan have not been invested. The investments are expected to be made in the fourth quarter of fiscal year 2014. All of the investments held in the Deferral Plan will be classified as trading securities and recorded at fair value with changes in the investments’ fair value recognized in the period they occur. The corresponding liability for the Deferral Plan is included in other non-current liability in the Company’s consolidated balance sheets.

Equity Incentive Plan

In June 2014, the Company’s shareholders approved the Amended and Restated 2007 Equity Incentive Plan (the Plan). The amendment to the Plan makes an additional 6 million shares of the Company’s common stock available for issuance and increases the maximum number of shares within the Plan that may be issued as restricted stock, restricted stock units (RSUs), stock grants and any other similar awards from 1.1 million to 1.5 million shares. As of September 30, 2014, awards issued under the Plan include both stock options and RSUs.

Stock Option Grants

The fair value of the stock options granted is estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions:

	Three Months						Nine Months
	Ended September 30,						Ended September 30,
	2013			2014			2013			2014
Expected stock price volatility	81.7		%	81.0		%	82.0		%	81.3		%
Risk free interest rate	1.8		%	1.9		%	1.3		%	1.9		%
Expected life of options (years)	6.25			6.25			6.25			6.25
Expected annual dividend per share	$	0.00		$	0.00		$	0.00		$	0.00

A summary of the Company’s stock options for the nine months ended September 30, 2014 is as follows:

	Number of Shares (in thousands)		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life	Aggregate Intrinsic Value (in millions)

Balance at December 31, 2013	9,041.1		$	5.65
Options granted	2,894.1		$	2.87
Options exercised	(594.4	)	$	3.53
Options forfeited	(1,012.3	)	$	5.82
Balance at September 30, 2014	10,328.5		$	4.97	6.9 years	$	17.6
Vested and unvested expected to vest, September 30, 2014	9,649.5		$	5.10	6.8 years	$	15.6
Exercisable at September 30, 2014	5,551.1		$	6.40	5.2 years	$	4.9

As of September 30, 2014, the total unrecognized compensation cost related to non-vested stock options granted was $8.3 million and is expected to be recognized over a weighted average period of 2.4 years.

Restricted Stock Units

In April 2014, the Compensation Committee made awards of restricted stock units (the RSUs) to certain employees of the Company. The RSUs awarded under the Plan are generally subject to graded vesting of 50% of the RSUs on the 13th month anniversary of the grant date and the remaining 50% of the RSUs on the 20th month anniversary of the grant date, in each case, contingent on such employee’s continued service on such date.

RSUs are generally subject to forfeiture if employment terminates prior to the release of vesting restrictions. The Company expenses the cost of the RSUs, which is determined to be the fair market value of the shares of common stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse.

A summary of non-vested RSU activity under the Plan for the nine months ended September 30, 2014 is as follows:

	Number of Shares (in thousands)		Weighted Average Grant Date Fair Value		Weighted Average Remaining Years	Aggregate Intrinsic Value (in millions)

Non-vested units as of December 31, 2013	—		$	—
Granted	975		$	2.28
Vested	—		$	—
Forfeited	(20	)	$	2.15
Non-vested units as of September 30, 2014	955		$	2.28	1.0	$	3.5

For the nine months ended September 30, 2014, there were no RSUs that vested and all non-vested units are expected to vest over their normal term. As of September 30, 2014, there was $1.5 million of total unrecognized compensation cost related to unvested RSUs with service-based vesting conditions. These costs are expected to be recognized over a weighted average period of 1.0 years.

In April 2014, the Board of Directors approved the Company’s Restricted Stock Unit Deferral Plan (the Deferred Compensation Plan), which provides selected employees with an opportunity to defer receipt of RSUs until the first to occur of termination of the employee’s employment or a date selected by the employee. Any RSUs deferred under the Deferred Compensation Plan would be fully vested once the original vesting conditions of the RSU were satisfied.

Compensation Expense Related to Equity Awards

The following table summarizes information related to compensation expense recognized in the statements of operations related to the equity awards (in thousands):

	Three Months				Nine Months
	Ended September 30,				Ended September 30,
	2013		2014		2013		2014
Stock compensation expense recognized in:
Research and development expense	$	824	$	698	$	2,634	$	1,950
General and administrative expense	693		953		2,040		2,448
Total stock compensation expense	$	1,517	$	1,651	$	4,674	$	4,398

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Assets and Liabilities Measured at Fair Value

9 Months Ended

Sep. 30, 2014

Assets and Liabilities Measured at Fair Value

Assets and Liabilities Measured at Fair Value

Note 8. Assets and Liabilities Measured at Fair Value

The Company’s financial assets and liabilities are measured at fair value and classified within the fair value hierarchy which is defined as follows:

Level 1 — Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.

Level 2 — Inputs other than quoted prices in active markets that are observable for the asset or liability, either directly or indirectly.

Level 3 — Inputs that are unobservable for the asset or liability.

Cash, Money Market Funds and Marketable Securities

The Company classifies its cash and money market funds within the fair value hierarchy as Level 1 as these assets are valued using quoted prices in active market for identical assets at the measurement date. The Company considers its investments in marketable securities as available-for-sale and classifies these assets within the fair value hierarchy as Level 2 primarily utilizing broker quotes in a non-active market for valuation of these securities. No changes in valuation techniques or inputs occurred during the three and nine months ended September 30, 2014. No transfers of assets between Level 1 and Level 2 of the fair value measurement hierarchy occurred during the three and nine months ended September 30, 2014.

Secured Debt

As disclosed in Note 9, the Company entered into a loan and security agreement (the 2013 Loan Agreement) with MidCap Funding III, LLC, Oxford Finance LLC and Silicon Valley Bank (SVB) in December 2013. The Company also entered into an equipment loan with SVB in 2011. The carrying amount of the Company’s borrowings approximates fair value at September 30, 2014. The Company’s secured debt is classified as Level 2 and the fair value is estimated using quoted prices for similar liabilities in active markets, as well as inputs that are observable for the liability (other than quoted prices), such as interest rates that are observable at commonly quoted intervals.

In connection with the 2013 Loan Agreement, as disclosed in Note 9, the Company recorded a contingent liability of approximately $0.3 million representing the fair value of a contingent payment of up to $0.4 million related to a success fee payable within six months of a trigger event, with the trigger event being regulatory acceptance of a New Drug Application (NDA) or the Marketing Authorization Application (MAA) submission. This is effective five years from the closing of the 2013 Loan Agreement. The success fee payable to the lender was probability adjusted and discounted utilizing an appropriate discount rate and classified as Level 3.

For the nine months ended September 30, 2014, change in fair value of the contingent success fee payable was $30 thousand, and is recorded in other income/(expense) in the Company’s consolidated statements of operations.

	(in thousands)
Fair value balance at December 31, 2013	$	264
Change in fair value	30
Fair value balance at September 30, 2014	$	294

Contingent Consideration Payable

The Company recorded a liability upon the acquisition of Callidus to estimate the fair value of future contingent consideration payments which may be made to former Callidus stockholders, as outlined under the terms of the merger agreement with Callidus. These contingent payments are owed if upon the achievement by the Company of certain clinical milestones of up to $35 million and regulatory approval milestones of up to $105 million as set forth in the Merger Agreement, provided that the aggregate consideration shall not exceed $130 million. The fair values of these Level 3 liabilities are estimated using a probability-weighted discounted cash flow analysis. Such valuations require significant estimates and assumptions including but not limited to: determining the timing and estimated costs to complete the in-process projects, projecting regulatory approvals, estimating future cash flows, and developing appropriate discount rates.

Subsequent changes in the fair value of these contingent consideration liabilities are recorded to the “Change in fair value of contingent consideration payable” expense line item in the consolidated statements of operations under operating expenses. For the nine months ended September 30, 2014, the recognized amount of the contingent consideration payable decreased by $0.4 million as a result of changes in certain probability factors and the time value of money.

	(in thousands)
Fair value balance at December 31, 2013	$	10,600
Change in fair value	(400		)
Fair value balance at September 30, 2014	$	10,200

Warrants

The Company allocated $3.3 million of proceeds from its March 2010 registered direct offering to warrants issued in connection with the offering that was classified as a liability. The valuation of the warrants was determined using the Black-Scholes model. The Company determined the warrant liability is most appropriately classified within Level 3 of the fair value hierarchy. This liability was subject to a fair value mark-to-market adjustment each period and the Company recognized the change in the fair value of the warrant liability as non-operating expense of $0.3 million for the three months ended March 31, 2013 and the resulting fair value of the warrant liability at March 31, 2013 was $1.2 million. The warrants expired on March 2, 2014 and hence the warrant liability is no longer recognized on the consolidated balance sheet as of September 30, 2014.

A summary of the fair value of the Company’s assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December 31, 2013, are identified in the following table (in thousands):

	Level 1		Level 2		Total
*Assets:*
Cash/ money market funds	$	43,640	$	—	$	43,640
Corporate debt securities	—		30,812		30,812
Commercial paper	—		7,198		7,198
Certificate of deposit	—		350		350
	$	43,640	$	38,360	$	82,000

	Level 1		Level 2		Level 3		Total
*Liabilities:*
Secured debt	$	—	$	14,473	$	—	$	14,473
Contingent success fee payable	—		—		264		264
Contingent consideration payable	—		—		10,600		10,600
Warrants liability	—		—		—		—
	$	—	$	14,473	$	10,864	$	25,337

A summary of the fair value of the Company’s assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of September 30, 2014, are identified in the following table (in thousands):

	Level 1		Level 2		Total
*Assets:*
Cash/ money market funds	$	19,671	$	—	$	19,671
Corporate debt securities	—		53,662		53,662
Commercial paper	—		11,499		11,499
Certificate of deposit	—		350		350
	$	19,671	$	65,511	$	85,182

	Level 1		Level 2		Level 3		Total
*Liabilities:*
Secured debt	$	—	$	14,302	$	—	$	14,302
Contingent success fee payable	—		—		294		294
Contingent consideration payable	—		—		10,200		10,200
	$	—	$	14,302	$	10,494	$	24,796

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Collaborative Agreements	9 Months Ended
Collaborative Agreements	Sep. 30, 2014
Collaborative Agreements
Collaborative Agreements	Note 10. Collaborative Agreements GSK In October 2010, the Company entered into the Original Collaboration Agreement with Glaxo Group Limited, an affiliate of GSK, to develop and commercialize migalastat. Under the terms of the Original Collaboration Agreement, GSK received an exclusive worldwide license to develop, manufacture and commercialize migalastat. In consideration of the license grant, the Company received an upfront, license payment of $30 million from GSK and was eligible to receive further payments of approximately $173.5 million upon the successful achievement of development, regulatory and commercialization milestones, as well as tiered double-digit royalties on global sales of migalastat GSK and the Company were jointly funding development costs in accordance with an agreed upon development plan. Additionally, GSK purchased approximately 6.9 million shares of the Company’s common stock at $4.56 per share, a 30% premium on the average price per share of the Company’s stock over a 60 day period preceding the closing date of the transaction. The total value of this equity investment to the Company was approximately $31 million. In July 2012, the Company entered into the Expanded Collaboration Agreement with GSK pursuant to which the Company and GSK continue to develop and commercialize migalastat, currently in Phase 3 development for the treatment of Fabry disease. The Expanded Collaboration Agreement amended and replaced in its entirety the Original Collaboration Agreement. Under the terms of the Expanded Collaboration Agreement, the Company and GSK were to co-develop all formulations of migalastat for Fabry disease, including the development of migalastat co-formulated with an investigational enzyme replacement therapy (ERT) for Fabry disease (the Co-formulated Product). Additionally, simultaneous with entry into the Expanded Collaboration Agreement, Amicus and GSK entered into a Securities Purchase Agreement (the 2012 SPA) pursuant to which GSK purchased approximately 2.9 million shares of Amicus common stock at a price of $6.30 per share for proceeds of $18.6 million. In November 2013, Amicus entered into the Revised Agreement with GSK, pursuant to which Amicus has obtained global rights to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease. The Revised Agreement amends and replaces in its entirety the Expanded Collaboration Agreement entered into between Amicus and GSK in July 2012. Under the terms of the Revised Agreement, there was no upfront payment from Amicus to GSK. For the next-generation Fabry ERT (migalastat co-formulated with ERT), GSK is eligible to receive single-digit royalties on net sales in eight major markets outside the U.S. For migalastat monotherapy, GSK is eligible to receive post-approval and sales-based milestones up to $40 million, as well as tiered royalties in the mid-teens in eight major markets outside the U.S. Under the terms of the Revised Agreement, GSK will no longer jointly fund development costs for all formulations of migalastat. Biogen In September 2013, the Company entered into a license and collaboration agreement (the “Biogen Agreement”) with Biogen to discover, develop and commercialize novel small molecules that target the GCase enzyme for the treatment of Parkinson’s disease. Biogen was responsible for funding all discovery, development, and commercialization activities and the Company was reimbursed for all full-time employees working on the project as part of a cost sharing arrangement. In accordance with the revenue recognition guidance related to reimbursement of research and development expenses, the Company identified all deliverables at the inception of the Biogen Agreement. The Company has not commenced its planned principal operations (i.e. selling commercial products) and is therefore a development stage enterprise. The Company is only performing development of its compounds, and therefore, development activities are part of the Company’s ongoing central operations. Additionally, the Company has the following accounting policies: · Research and development expenses related to a collaboration agreement will be recorded on a gross basis in the income statement and not presented net of any reimbursement received from a collaboration agreement; and · The reimbursement of research and development expenses from a collaborator will be recognized in the income statement as “Research Revenue” for the period in which the research activity occurred. For the nine months ended September 30, 2014, the Company recognized $1.2 million in Research Revenue for work performed under the cost sharing arrangement of the Biogen Agreement. In September 2014, the Company and Biogen concluded their research collaboration. The Company’s most advanced Parkinson’s candidate is AT3375, which was developed outside the collaboration and is wholly-owned by the Company.

Description of Business and Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2014
Description of Business and Significant Accounting Policies
Basis of Presentation	*Basis of Presentation* The Company has prepared the accompanying unaudited consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10-01 of Regulations S-X. Accordingly, they do not include all of the information and disclosures required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying unaudited financial statements reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s interim financial information. The accompanying unaudited consolidated financial statements and related notes should be read in conjunction with the Company’s financial statements and related notes as contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013. For a complete description of the Company’s accounting policies, please refer to the Annual Report on Form 10-K for the fiscal year ended December 31, 2013.
Revenue Recognition	Revenue Recognition The Company recognizes revenue when amounts are realized or realizable and earned. Revenue is considered realizable and earned when the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the price is fixed or determinable; and (4) collection of the amounts due are reasonably assured. In multiple element arrangements, revenue is allocated to each separate unit of accounting and each deliverable in an arrangement is evaluated to determine whether it represents separate units of accounting. A deliverable constitutes a separate unit of accounting when it has standalone value and there is no general right of return for the delivered elements. In instances when the aforementioned criteria are not met, the deliverable is combined with the undelivered elements and the allocation of the arrangement consideration and revenue recognition is determined for the combined unit as a single unit of accounting. Allocation of the consideration is determined at arrangement inception on the basis of each unit’s relative selling price. In instances where there is determined to be a single unit of accounting, the total consideration is applied as revenue for the single unit of accounting and is recognized over the period of inception through the date where the last deliverable within the single unit of accounting is expected to be delivered. The Company’s current revenue recognition policies, which were applied in fiscal 2010, provide that, when a collaboration arrangement contains multiple deliverables, such as license and research and development services, the Company allocates revenue to each separate unit of accounting based on a selling price hierarchy. The selling price hierarchy for a deliverable is based on (i) its vendor specific objective evidence (VSOE) if available, (ii) third party evidence (TPE) if VSOE is not available, or (iii) best estimated selling price (BESP) if neither VSOE nor TPE is available. The Company would establish the VSOE of selling price using the price charged for a deliverable when sold separately. The TPE of selling price would be established by evaluating largely similar and interchangeable competitor products or services in standalone sales to similarly situated customers. The BESP would be established considering internal factors such as an internal pricing analysis or an income approach using a discounted cash flow model. The Company also considers the impact of potential future payments it makes in its role as a vendor to its customers and evaluates if these potential future payments could be a reduction of revenue from that customer. If the potential future payments to the customer are: · a payment for an identifiable benefit; and · the identifiable benefit is separable from the existing relationship between the Company and its customer; and · the identifiable benefit can be obtained from a party other than the customer; and · the Company can reasonably estimate the fair value of the identifiable benefit, then the payments are accounted for separate from the revenue received from that customer. If, however, all these criteria are not satisfied, then the payments are treated as a reduction of revenue from that customer. If the Company determines that any potential future payments to its customers are to be considered as a reduction of revenue, it must evaluate if the total amount of revenue to be received under the arrangement is fixed and determinable. If the total amount of revenue is not fixed and determinable due to the uncertain nature of the potential future payments to the customer, then any customer payments cannot be recognized as revenue until the total arrangement consideration becomes fixed and determinable. The reimbursements for research and development costs under collaboration agreements that meet the criteria for revenue recognition are included in Research Revenue and the costs associated with these reimbursable amounts are included in research and development expenses. In order to determine the revenue recognition for contingent milestones, the Company evaluates the contingent milestones using the criteria as provided by the Financial Accounting Standards Boards (FASB) guidance on the milestone method of revenue recognition at the inception of a collaboration agreement. The criteria requires that (i) the Company determines if the milestone is commensurate with either its performance to achieve the milestone or the enhancement of value resulting from the Company’s activities to achieve the milestone, (ii) the milestone be related to past performance, and (iii) the milestone be reasonable relative to all deliverable and payment terms of the collaboration arrangement. If these criteria are met then the contingent milestones can be considered as substantive milestones and will be recognized as revenue in the period that the milestone is achieved. Although the Company believes the assumptions and estimates made are reasonable, they are based in part on historical experience and information obtained from the management of the acquired businesses and are inherently uncertain. Examples of critical estimates in valuing any contingent acquisition consideration issued or which may be issued and the intangible assets we have acquired or may acquire in the future include but are not limited to: · the feasibility and timing of achievement of development, regulatory and commercial milestones; · expected costs to develop the in-process research and development into commercially viable products; and · future expected cash flows from product sales. Unanticipated events and circumstances may occur which may affect the accuracy or validity of such assumptions, estimates or actual results.
Fair Value Measurements	Fair Value Measurements The Company records certain asset and liability balances under the fair value measurements as defined by the FASB guidance. Current FASB fair value guidance emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, current FASB guidance establishes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity’s own assumptions that market participants assumptions would use in pricing assets or liabilities (unobservable inputs classified within Level 3 of the hierarchy). Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at measurement date. Level 2 inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals. Level 3 inputs are unobservable inputs for the asset or liability, which is typically based on an entity’s own assumptions, as there is little, if any, related market activity. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability.
New Accounting Standards	*New Accounting Standards* In August 2014, the FASB issued ASU 2014-15, “Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (ASU 2014-15), which defines management’s responsibility to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosures if there is substantial doubt about its ability to continue as a going concern. The pronouncement is effective for annual reporting periods ending after December 15, 2016 with early adoption permitted. The adoption of this guidance is not expected to have a significant impact on the Company’s consolidated financial statements. In June 2014, the FASB issued ASU 2014-10 that removes the definition of development stage entity from the accounting standards codification, thereby removing the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the ASU eliminates the requirements for development stage entities to (i) present inception-to-date information in the statement of income, cash flow and stockholders’ equity, (ii) label the financial statements as those of a development stage entity, (iii) disclose a description of the development stage activities in which the entity is engaged, and (iv) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. The Company has applied the ASU effective from the financial statements as of June 30, 2014. In May 2014, FASB issued ASU 2014-09, Revenue From Contracts With Customers, that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The ASU is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract. Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard. The ASU becomes effective for the Company at the beginning of its 2017 fiscal year; early adoption is not permitted. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.

- Definition

Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.

+ References + Details

Cash, Money Market Funds and Marketable Securities (Tables)

9 Months Ended

Sep. 30, 2014

Cash, Money Market Funds and Marketable Securities

Schedule of cash and available-for-sale securities

Cash and available-for-sale securities consisted of the following as of December 31, 2013 and September 30, 2014 (in thousands):

	As of December 31, 2013
	Cost		Unrealized Gain		Unrealized Loss			Fair Value
Cash balances	$	43,640	$	—	$	—		$	43,640
Corporate debt securities	30,817		1		(6		)	30,812
Commercial paper	7,192		6		—			7,198
Certificate of deposit	350		—		—			350
	$	81,999	$	7	$	(6	)	$	82,000

Included in cash and cash equivalents	$	43,640	$	—	$	—		$	43,640
Included in marketable securities	38,359		7		(6		)	38,360
Total cash and available for sale securities	$	81,999	$	7	$	(6	)	$	82,000

	As of September 30, 2014
	Cost		Unrealized Gain		Unrealized Loss			Fair Value
Cash balances	$	19,671	$	—	$	—		$	19,671
Corporate debt securities	53,674		1		(13		)	53,662
Commercial paper	11,486		13		—			11,499
Certificate of deposit	350		—		—			350
	$	85,181	$	14	$	(13	)	$	85,182

Included in cash and cash equivalents	$	19,671	$	—	$	—		$	19,671
Included in marketable securities	65,510		14		(13		)	65,511
Total cash and available for sale securities	$	85,181	$	14	$	(13	)	$	85,182

Schedule of changes in AOCI associated with the unrealized holding gain on available-for-sale investments

The changes in AOCI associated with the unrealized holding gain on available-for-sale investments during the three and nine months ended September 30, 2013 and 2014, were as follows (in thousands):

	Three Months Ended September 30,					Nine Months Ended September 30,
	2013		2014			2013			2014

Balance, beginning	$	3	(2		)	$	14		$	1
Current period changes in fair value, (a)	2		4			(9		)	1
Reclassification of earnings, (a)	—		—			—			—
Balance, ending	$	5	$	2		$	5		$	2

(a) — Taxes have not been accrued on the unrealized gain on securities as the Company is in a loss position for all periods presented.

Basic and Diluted Net Loss Attributable to Common Stockholders per Common Share (Tables)

9 Months Ended

Sep. 30, 2014

Basic and Diluted Net Loss Attributable to Common Stockholders per Common Share

Schedule of reconciliation of the numerator and denominator used in computing basic and diluted net loss attributable to common stockholders per common share

	Three Months Ended September 30,						Nine Months Ended September 30,
(In thousands, except per share amounts)	2013			2014			2013			2014
Historical
Numerator:
Net loss attributable to common stockholders per common	$	(14,589	)	$	(17,149	)	$	(47,396	)	$	(47,706	)

Denominator
Weighted average common shares outstanding — basic and diluted	49,621,188			78,889,346			49,621,188			70,216,251

Schedule of potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method

The table below presents potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method (in thousands):

	As of September 30,
	2013	2014
Options to purchase common stock	10,112	10,329
Outstanding warrants, convertible to common stock	1,404	1,600
Unvested restricted stock units	—	955
Total number of potentially issuable shares	11,516	12,884

Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2014

Stockholders' Equity

Schedule of fair value weighted-average assumptions

	Three Months						Nine Months
	Ended September 30,						Ended September 30,
	2013			2014			2013			2014
Expected stock price volatility	81.7		%	81.0		%	82.0		%	81.3		%
Risk free interest rate	1.8		%	1.9		%	1.3		%	1.9		%
Expected life of options (years)	6.25			6.25			6.25			6.25
Expected annual dividend per share	$	0.00		$	0.00		$	0.00		$	0.00

Summary of stock options

	Number of Shares (in thousands)		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life	Aggregate Intrinsic Value (in millions)

Balance at December 31, 2013	9,041.1		$	5.65
Options granted	2,894.1		$	2.87
Options exercised	(594.4	)	$	3.53
Options forfeited	(1,012.3	)	$	5.82
Balance at September 30, 2014	10,328.5		$	4.97	6.9 years	$	17.6
Vested and unvested expected to vest, September 30, 2014	9,649.5		$	5.10	6.8 years	$	15.6
Exercisable at September 30, 2014	5,551.1		$	6.40	5.2 years	$	4.9

Summary of information on the Company's restricted stock

	Number of Shares (in thousands)		Weighted Average Grant Date Fair Value		Weighted Average Remaining Years	Aggregate Intrinsic Value (in millions)

Non-vested units as of December 31, 2013	—		$	—
Granted	975		$	2.28
Vested	—		$	—
Forfeited	(20	)	$	2.15
Non-vested units as of September 30, 2014	955		$	2.28	1.0	$	3.5

Summary of information related to compensation expense recognized in the statements of operations

The following table summarizes information related to compensation expense recognized in the statements of operations related to the equity awards (in thousands):

	Three Months				Nine Months
	Ended September 30,				Ended September 30,
	2013		2014		2013		2014
Stock compensation expense recognized in:
Research and development expense	$	824	$	698	$	2,634	$	1,950
General and administrative expense	693		953		2,040		2,448
Total stock compensation expense	$	1,517	$	1,651	$	4,674	$	4,398

Assets and Liabilities Measured at Fair Value (Tables)

9 Months Ended

Sep. 30, 2014

Assets and Liabilities Measured at Fair Value

Schedule of changes in contingent success fee payable

	(in thousands)
Fair value balance at December 31, 2013	$	264
Change in fair value	30
Fair value balance at September 30, 2014	$	294

Schedule of changes in contingent consideration payable

	(in thousands)
Fair value balance at December 31, 2013	$	10,600
Change in fair value	(400		)
Fair value balance at September 30, 2014	$	10,200

Schedule of financial assets and liabilities subject to fair value measurements

	Level 1		Level 2		Total
*Assets:*
Cash/ money market funds	$	43,640	$	—	$	43,640
Corporate debt securities	—		30,812		30,812
Commercial paper	—		7,198		7,198
Certificate of deposit	—		350		350
	$	43,640	$	38,360	$	82,000

	Level 1		Level 2		Level 3		Total
*Liabilities:*
Secured debt	$	—	$	14,473	$	—	$	14,473
Contingent success fee payable	—		—		264		264
Contingent consideration payable	—		—		10,600		10,600
Warrants liability	—		—		—		—
	$	—	$	14,473	$	10,864	$	25,337

	Level 1		Level 2		Total
*Assets:*
Cash/ money market funds	$	19,671	$	—	$	19,671
Corporate debt securities	—		53,662		53,662
Commercial paper	—		11,499		11,499
Certificate of deposit	—		350		350
	$	19,671	$	65,511	$	85,182

	Level 1		Level 2		Level 3		Total
*Liabilities:*
Secured debt	$	—	$	14,302	$	—	$	14,302
Contingent success fee payable	—		—		294		294
Contingent consideration payable	—		—		10,200		10,200
	$	—	$	14,302	$	10,494	$	24,796

Description of Business and Significant Accounting Policies (Details) $ / shares in Units, $ in Thousands, shares in Millions	1 Months Ended		3 Months Ended	9 Months Ended
	Aug. 31, 2014 item	Nov. 30, 2013 USD ($) item $ / shares	Jul. 31, 2014 USD ($) $ / shares shares	Sep. 30, 2014 USD ($) $ / shares	Dec. 31, 2013 USD ($) $ / shares
Corporate Information, Status of Operations and Management Plans
Number of patients with GLP HEK-amenable mutation who completed study 012 \| item	48
Number of patients elected to continue with treatment extension \| item	46
Patients elected to continue with 12 month treatment extension (as a percent)	96.00%
Term of treatment extension	12 months
Number of patients remain on migalastate \| item	45
Common stock, par value (in dollars per share) \| $ / shares				$ 0.01	$ 0.01
Proceeds from the issuance of common stock (in dollars) \| $				$ 38,736
Remaining term of the warrants				1 year
Accumulated deficit \| $				$ 426,228	$ 378,522
SPA
Corporate Information, Status of Operations and Management Plans
Common stock, par value (in dollars per share) \| $ / shares		$ 0.01
Exercise price of warrants (in dollars per share) \| $ / shares		2.50
Aggregate offering proceeds \| $		$ 15,000
Cowen and Company, LLC \| Sales Agreement
Corporate Information, Status of Operations and Management Plans
Issuance of common stock \| $			$ 40,000
Common stock, par value (in dollars per share) \| $ / shares			$ 0.01
Proceeds from the issuance of common stock (in dollars) \| $			$ 38,700
Common stock issued (in shares) \| shares			14.3
GSK \| Revised Agreement
Corporate Information, Status of Operations and Management Plans
Number of major markets outside the U.S. from whom parties to contractual arrangement is eligible to receive single-digit royalties on net sales \| item		8
Number of major markets outside the U.S. from whom parties to contractual arrangement is eligible to receive post-approval and sales-based milestones \| item		8

Cash, Money Market Funds and Marketable Securities (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Cash, Money Market Funds, and Marketable Securities
Cash and cash equivalents, Amortized Cost	$ 19,671	$ 30,047	$ 19,671	$ 30,047	$ 43,640	$ 33,971
Cash and cash equivalents, Fair Value	19,671		19,671		43,640
Marketable securities, Amortized Cost	65,510		65,510		38,359
Unrealized Gain	14		14		7
Unrealized Loss	(13)		(13)		(6)
Marketable securities, Fair Value	65,511		65,511		38,360
Cash and marketable securities, Amortized Cost	85,181		85,181		81,999
Cash and marketable securities, Fair Value	85,182		85,182		82,000
Available-for-sale investments
Realized gain (loss) on securities available-for-sale			0		0
Fair value of available for sale securities in unrealized loss positions	42,600		42,600		23,600
Changes in AOCI associated with the unrealized holding gain on available-for-sale investments
Balance, beginning	(2)	3	1	14	14
Current period changes in fair value	4	2	1	(9)	(13)
Balance, ending	2	$ 5	2	$ 5	1
Corporate debt securities
Cash, Money Market Funds, and Marketable Securities
Marketable securities, Amortized Cost	53,674		53,674		30,817
Unrealized Gain	1		1		1
Unrealized Loss	(13)		(13)		(6)
Marketable securities, Fair Value	53,662		53,662		30,812
Commercial paper
Cash, Money Market Funds, and Marketable Securities
Marketable securities, Amortized Cost	11,486		11,486		7,192
Unrealized Gain	13		13		6
Marketable securities, Fair Value	11,499		11,499		7,198
Certificate of deposit
Cash, Money Market Funds, and Marketable Securities
Marketable securities, Amortized Cost	350		350		350
Marketable securities, Fair Value	$ 350		$ 350		$ 350

Acquisition of Callidus Biopharma, Inc. (Details) - USD ($) $ / shares in Units, shares in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Nov. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Acquisition of Callidus Biopharma, Inc.
Common stock, par value (in dollars per share)		$ 0.01		$ 0.01		$ 0.01
Contingent acquisition consideration payable		$ 10,200,000		$ 10,200,000		$ 10,600,000
Decrease in the contingent consideration payable		600,000		$ 400,000
Supplemental Pro Forma Information
Net loss			$ (15,838,000)		$ (49,569,000)
Callidus
Acquisition of Callidus Biopharma, Inc.
Common stock issued on acquisition (in shares)	7,200			25
Common stock, par value (in dollars per share)	$ 0.01
Maximum merger consideration to be transferred	$ 130,000,000
Milestone payment that can be settled in equity	$ 40,000,000
Number of trading days immediately preceding the date of payment on basis of which issue price will be determined	10 days
Discount rate (as a percent)	13.00%
Contingent acquisition consideration payable	$ 10,600,000	10,200,000		$ 10,200,000		$ 10,600,000
Decrease in the contingent consideration payable				400,000
Intangible assets-(IPR&D)		23,000,000		23,000,000
Deferred tax liability		9,200,000		9,200,000
Goodwill expected to be deductible for income tax purposes		$ 0		$ 0
Callidus \| Maximum
Acquisition of Callidus Biopharma, Inc.
Additional payment to be made upon achievement of clinical milestones	35,000,000
Additional payment to be made upon achievement of regulatory approval milestones	$ 105,000,000

Stockholders' Equity (Details) $ / shares in Units, $ in Thousands	1 Months Ended				3 Months Ended	9 Months Ended
	Oct. 31, 2014 $ / shares shares	Jun. 30, 2014 shares	Nov. 30, 2013 USD ($) $ / shares shares	Jul. 31, 2012 $ / shares shares	Jul. 31, 2014 USD ($) $ / shares shares	Sep. 30, 2014 USD ($) item $ / shares shares	Dec. 31, 2013 $ / shares shares
Stockholders' Equity
Authorized number of shares of common stock						125,000,000	125,000,000
Voting right for each share held, number \| item						1
Collaborative Agreements
Common stock, par value (in dollars per share) \| $ / shares						$ 0.01	$ 0.01
Aggregate offering proceeds from issuance of common stock (in dollars) \| $						$ 38,736
Remaining term of the warrants						1 year
2007 Equity Incentive Plan
Collaborative Agreements
Additional common stock authorized (in shares)		6,000,000
2007 Equity Incentive Plan \| Minimum
Collaborative Agreements
Granted (in shares)						1,100,000
2007 Equity Incentive Plan \| Maximum
Collaborative Agreements
Granted (in shares)						1,500,000
Callidus
Collaborative Agreements
Common stock, par value (in dollars per share) \| $ / shares			$ 0.01
Common stock issued on acquisition (in shares)			7,200,000			25,000
Warrants
Collaborative Agreements
Offering price (in dollars per share) \| $ / shares						$ 2.12
Number of inputs used to determine the value of the warrants \| item						6
Exercise price of warrants (in dollars per share) \| $ / shares						$ 2.50
Remaining term of the warrants						1 year
Volatility (as a percent)						93.50%
Annual rate of dividends (as a percent)						0.00%
Riskless rate of return (as a percent)						0.12%
Value of the warrants \| $						$ 1,000
SPA
Collaborative Agreements
Common stock, par value (in dollars per share) \| $ / shares			$ 0.01
Exercise price of warrants (in dollars per share) \| $ / shares			2.50
Proceeds received from private placement \| $			$ 15,000
Cowen \| Sales Agreement
Collaborative Agreements
Common stock, par value (in dollars per share) \| $ / shares					$ 0.01
Aggregate offering proceeds from issuance of common stock (in dollars) \| $					$ 38,700
Fixed commission rate as a percentage of gross proceeds per Share sold					3.00%
Common stock issued (in shares)					14,300,000
Commission expenses incurred on issue of common stock \| $					$ 1,100
Legal fees incurred on issue of common stock \| $					$ 100
GSK \| Subsequent event
Collaborative Agreements
Common stock issued (in shares)	11,315,825
Offering price (in dollars per share) \| $ / shares	$ 5.29
GSK \| SPA
Collaborative Agreements
Stock issued from collaboration agreement (in shares)			1,500,000	2,900,000
Offering price (in dollars per share) \| $ / shares			$ 2.00	$ 6.30
Redmile Group \| SPA
Collaborative Agreements
Number of shares represented by units issued			6,000,000
Price per unit (in dollars per share) \| $ / shares			$ 2.00
Number of shares of common stock sold in a unit			1
Number of warrants sold in a unit (in shares)			0.267
Stock issued from collaboration agreement (in shares)			6,000,000
Warrants issued (in shares)			1,600,000

Stockholders' Equity (Details 2) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	3 Months Ended		9 Months Ended
	Apr. 30, 2014	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Stock options plans
Fair value weighted-average assumptions:
Expected stock price volatility (as a percent)		81.00%	81.70%	81.30%	82.00%
Risk free interest rate (as a percent)		1.90%	1.80%	1.90%	1.30%
Expected life of options		6 years 3 months	6 years 3 months	6 years 3 months	6 years 3 months
Expected annual dividend per share (in dollars per share)		$ 0.00	$ 0.00	$ 0.00	$ 0.00
Number of Shares
Balance at the beginning of the period (in shares)				9,041,100
Options granted (in shares)				2,894,100
Options exercised (in shares)				(594,400)
Options forfeited (in shares)				(1,012,300)
Balance at the end of the period (in shares)		10,328,500		10,328,500
Vested and unvested expected to vest at the end of the period (in shares)		9,649,500		9,649,500
Exercisable at the end of the period (in shares)		5,551,100		5,551,100
Weighted Average Exercise Price
Balance at the beginning of the period (in dollars per share)				$ 5.65
Options granted (in dollars per share)				2.87
Options exercised (in dollars per share)				3.53
Options forfeited (in dollars per share)				5.82
Balance at the end of the period (in dollars per share)		$ 4.97		4.97
Vested and unvested expected to vest at the end of the period (in dollars per share)		5.10		5.10
Exercisable at the end of the period (in dollars per share)		$ 6.40		$ 6.40
Weighted Average Remaining Contractual Life
Balance at the end of the period				6 years 10 months 24 days
Vested and unvested expected to vest at the end of the period				6 years 9 months 18 days
Exercisable at the end of the period				5 years 2 months 12 days
Aggregate Intrinsic Value
Aggregate intrinsic value of options outstanding		$ 17.6		$ 17.6
Aggregate intrinsic value of options vested and unvested expected to vest		15.6		15.6
Aggregate intrinsic value of options exercisable		4.9		4.9
Total unrecognized compensation cost related to non-vested stock options granted		$ 8.3		$ 8.3
Period of recognition compensation cost				2 years 4 months 24 days
Restricted Stock Units
Aggregate Intrinsic Value
Period of recognition compensation cost				1 year
Number of Shares
Granted (in shares)				975,000
Forfeited (in shares)				(20,000)
Non-vested units at the end of the period		955,000		955,000
Weighted Average Grant Date Fair Value
Granted (in dollars per shares)				$ 2.28
Forfeited (in dollars per shares)				2.15
Non-vested units at the end of the period		$ 2.28		$ 2.28
Weighted Average Remaining Contractual Life
Non-vested units at the end of period				1 year
Aggregate Intrinsic Value
Non-vested units at the end of the period		$ 3.5		$ 3.5
Shares vested and expected to vest				0
Unrecognized compensation cost related to unvested restricted stock awards (in dollars)		$ 1.5		$ 1.5
Restricted Stock Units \| Vesting on 13th month anniversary of grant date
Aggregate Intrinsic Value
Vesting rights percentage	50.00%
Restricted Stock Units \| Vesting on 20th month anniversary of grant date
Aggregate Intrinsic Value
Vesting rights percentage	50.00%

Assets and Liabilities Measured at Fair Value (Details) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended			9 Months Ended
	Nov. 30, 2013	Mar. 31, 2010	Sep. 30, 2014	Sep. 30, 2013	Mar. 31, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Assets and Liabilities Measured at Fair Value
Transfer of assets from Level 1 to Level 2								$ 0
Transfer of assets from Level 2 to Level 1								0
Change in fair value of warrant liability				$ (517)	$ 300		$ (874)
Warrant liability					$ 1,200
Contingent consideration payable
Balance at the beginning of the period						$ 10,600
Change in fair value			$ (600)			(400)
Balance at the end of the period			10,200			10,200
Assets:
Cash/money market funds				$ 30,047			$ 30,047	19,671	$ 43,640	$ 33,971
Liabilities:
Contingent consideration payable			10,200			10,600		10,200	10,600
Level 1
Assets:
Cash/money market funds								19,671	43,640
Fair value of assets								19,671	43,640
Level 2
Assets:
Fair value of assets								65,511	38,360
Liabilities:
Secured debt								14,302	14,473
Fair value of liabilities								14,302	14,473
Level 2 \| Corporate debt securities
Assets:
Fair value of assets								53,662	30,812
Level 2 \| Commercial paper
Assets:
Fair value of assets								11,499	7,198
Level 2 \| Certificate of deposit
Assets:
Fair value of assets								350	350
Level 3
Financial assets and liabilities subject to fair value measurements
Contingent success fee payable			294			264		294	264
Contingent success fee payable
Balance at the beginning of the period						264
Balance at the end of the period			294			294
Contingent consideration payable
Balance at the beginning of the period						10,600
Balance at the end of the period			10,200			10,200
Liabilities:
Contingent success fee payable			294			264		294	264
Contingent consideration payable			10,200			10,600		10,200	10,600
Fair value of liabilities								10,494	10,864
Total
Financial assets and liabilities subject to fair value measurements
Contingent success fee payable			294			264		294	264
Contingent success fee payable
Balance at the beginning of the period						264
Balance at the end of the period			294			294
Contingent consideration payable
Balance at the beginning of the period						10,600
Balance at the end of the period			10,200			10,200
Assets:
Cash/money market funds								19,671	43,640
Fair value of assets								85,182	82,000
Liabilities:
Secured debt								14,302	14,473
Contingent success fee payable			294			264		294	264
Contingent consideration payable			10,200			10,600		10,200	10,600
Fair value of liabilities								24,796	25,337
Total \| Corporate debt securities
Assets:
Fair value of assets								53,662	30,812
Total \| Commercial paper
Assets:
Fair value of assets								11,499	7,198
Total \| Certificate of deposit
Assets:
Fair value of assets								350	350
SPA
Contingent consideration payable
Proceeds from issuance of warrants		$ 3,300
Callidus
Contingent success fee payable
Maximum merger consideration to be transferred	$ 130,000
Contingent consideration payable
Balance at the beginning of the period						10,600
Change in fair value						(400)
Balance at the end of the period	10,600		10,200			10,200
Liabilities:
Contingent consideration payable	10,600		10,200			10,200		10,200	10,600
Callidus \| Maximum
Contingent success fee payable
Additional payment to be made upon achievement of clinical milestones	35,000
Additional payment to be made upon achievement of regulatory approval milestones	$ 105,000
2013 Loan Agreement
Financial assets and liabilities subject to fair value measurements
Fair value of contingent payment						300
Contingent success fee payable			294			$ 264		294	264
Period of trigger event within which success fee is payable						6 months
Period of effectiveness of trigger event from closing of loan						5 years
Contingent success fee payable
Balance at the beginning of the period						$ 264
Change in fair value						30
Balance at the end of the period			294			294
Liabilities:
Contingent success fee payable			294			264		294	$ 264
2013 Loan Agreement \| Maximum
Financial assets and liabilities subject to fair value measurements
Contingent success fee payable			400			400		400
Contingent success fee payable
Balance at the end of the period			400			400
Liabilities:
Contingent success fee payable			$ 400			$ 400		$ 400

Short-Term Borrowings and Long-Term Debt (Details) $ in Thousands	1 Months Ended	3 Months Ended	9 Months Ended
	Feb. 29, 2012 USD ($)	Sep. 30, 2014 USD ($) item	Sep. 30, 2014 USD ($) item	Dec. 31, 2013 USD ($)
2013 Loan Agreement
Short-Term Borrowings and Long-Term Debt
Maximum amount of loan				$ 25,000
Long-term portion, gross of debt discount		$ 15,000	$ 15,000	15,000
Fixed interest rate (as a percent)		8.50%	8.50%
Number of equal monthly installments for repayment of debt \| item		33	33
Debt discount				800
Debt facility fee		$ 100	$ 100
Contingent exit fee payable		400	400
Fair value of contingent payment			300
Contingent success fee payable		294	$ 294	$ 264
Period of trigger event within which success fee is payable			6 months
Period of effectiveness of trigger event from closing of loan			5 years
Amortization of debt discount		45	$ 131
Amortization of deferred financing costs		6	18
2013 Loan Agreement \| Maximum
Short-Term Borrowings and Long-Term Debt
Amount available for borrowing		10,000	10,000
Contingent success fee payable		400	400
2011 Loan Agreement
Short-Term Borrowings and Long-Term Debt
Long-term portion, gross of debt discount		$ 0	$ 0
Amount borrowed	$ 1,000
Period for repayment of debt	2 years 6 months

Collaborative Agreements (Details) $ / shares in Units, $ in Thousands, shares in Millions	1 Months Ended			3 Months Ended		9 Months Ended
	Nov. 30, 2013 USD ($) item $ / shares shares	Jul. 31, 2012 USD ($) $ / shares shares	Oct. 31, 2010 USD ($) $ / shares shares	Sep. 30, 2014 USD ($)	Sep. 30, 2013 USD ($)	Sep. 30, 2014 USD ($)	Sep. 30, 2013 USD ($)
Collaborative Agreements
Total value of the equity investment to the company						$ 38,736
Research revenue for work performed under cost sharing arrangement				$ 293	$ 39	1,224	$ 39
GSK \| Original Collaboration Agreement
Collaborative Agreements
Upfront payment received			$ 30,000
Potential milestone payments receivable			$ 173,500
Stock issued from collaboration agreement (in shares) \| shares			6.9
Price per share of common stock issued as part of the license and collaboration agreement (in dollars per share) \| $ / shares			$ 4.56
Percentage of premium on average price per share of common stock issued as part of the license and collaboration agreement			30.00%
Period preceding the closing date of the transaction over which average price per share of the company's stock is used			60 days
Total value of the equity investment to the company			$ 31,000
GSK \| SPA
Collaborative Agreements
Stock issued from collaboration agreement (in shares) \| shares	1.5	2.9
Price per share of common stock issued as part of the license and collaboration agreement (in dollars per share) \| $ / shares	$ 2.00	$ 6.30
Total purchase price (in dollars)		$ 18,600
GSK \| Revised Agreement
Collaborative Agreements
Upfront payment received	$ 0
Number of major markets outside the U.S. from whom parties to contractual arrangement is eligible to receive single-digit royalties on net sales \| item	8
Number of major markets outside the U.S. from whom parties to contractual arrangement is eligible to receive post-approval and sales-based milestones \| item	8
GSK \| Revised Agreement \| Maximum
Collaborative Agreements
Potential milestone payments upon achievement of post-approval and sales-based milestones	$ 40,000
Biogen Idec
Collaborative Agreements
Research revenue for work performed under cost sharing arrangement						$ 1,200

Restructuring Charges (Details) $ in Thousands	1 Months Ended		3 Months Ended		9 Months Ended
Restructuring Charges (Details) $ in Thousands	Dec. 31, 2013 USD ($) item	Nov. 30, 2013 item	Sep. 30, 2014 USD ($)	Dec. 31, 2013 USD ($)	Sep. 30, 2014 USD ($)
Restructuring charges
Restructuring charges			$ 15	$ 2,000	$ (74)
Summary of restructuring charges and utilization
Balance at the beginning of the period					1,842
Cash Payments					(1,361)
Adjustments					(74)
Balance at the end of the period	$ 1,842		407	1,842	407
Employment termination costs
Restructuring charges
Employees eliminated (as a percent)		14.00%
Number of employees eliminated \| item		15
Restructuring charges				1,200
Restructuring charges unpaid and classified under accrued expenses			77		77
Summary of restructuring charges and utilization
Balance at the beginning of the period					1,139
Cash Payments					(1,062)
Balance at the end of the period	$ 1,139		77	1,139	77
Facilities consolidation
Restructuring charges
Number of subleased locations that were closed in consolidation \| item	1
Restructuring charges				800
Lease payments				700
Write-down of the net book value of fixed assets				100
Summary of restructuring charges and utilization
Balance at the beginning of the period					703
Cash Payments					(299)
Adjustments					(74)
Balance at the end of the period	$ 703		$ 330	$ 703	$ 330

Subsequent Events	9 Months Ended
Subsequent Events	Sep. 30, 2014
Subsequent Events
Subsequent Events	Note 12. Subsequent Events In October 2014, GSK sold 11,315,825 shares of our common stock at a price of $5.29 per share, representing their entire holdings in our common stock. We did not sell any shares or receive any proceeds and the total number of shares of our outstanding common stock did not change as a result of this sale.

Goodwill (Details) $ in Millions	1 Months Ended
Goodwill (Details) $ in Millions	Nov. 30, 2013 USD ($)
Changes in goodwill
Change in goodwill related to the acquisition of Callidus	$ 11.6

Intangible Assets (Details) $ in Millions	1 Months Ended
Intangible Assets (Details) $ in Millions	Nov. 30, 2013 USD ($)
Changes in IPR&D
IPR&D related to the acquisition of Callidus	$ 23.0

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2014	Dec. 31, 2013
Consolidated Balance Sheets
Accumulated depreciation and amortization of property and equipment (in dollars)	$ 11,157	$ 9,973
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	125,000,000	125,000,000
Common stock, shares issued	79,257,588	61,975,416
Common stock, shares outstanding	79,257,588	61,975,416

Stockholders' Equity (Details 3) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Stockholders' Equity (Details 3) - USD ($) $ in Thousands	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Stock compensation expense
Total stock compensation expense	$ 1,651	$ 1,517	$ 4,398	$ 4,674
Research and development expense
Stock compensation expense
Total stock compensation expense	698	824	1,950	2,634
General and administrative expense
Stock compensation expense
Total stock compensation expense	$ 953	$ 693	$ 2,448	$ 2,040

Subsequent Events (Details) - GSK - $ / shares	1 Months Ended
Subsequent Events (Details) - GSK - $ / shares	Oct. 31, 2014	Nov. 30, 2013	Jul. 31, 2012
SPA
Subsequent Events
Share Price		$ 2.00	$ 6.30
Subsequent event
Subsequent Events
Common stock issued (in shares)	11,315,825
Share Price	$ 5.29